NeoGenomics Gains 'Unexpected' Win As Court Rejects Natera Claims

A District Court ruling invalidated specific Natera patents, clearing the path for NeoGenomics to broadly commercialize its RaDaR ST assay, which had been previously constrained. While Natera evaluates an appeal and asserts the decision does not impact a separate key patent that led to a prior injunction, NeoGenomics has already launched RaDaR ST for biopharma clients and submitted for CMS reimbursement. Analysts at William Blair view this as an unexpected positive, projecting a potential Q4 2025 commercial launch, which propelled NeoGenomics' stock up 24.55%, though they maintain a Market Perform rating, awaiting greater execution confidence.

Analysis

A U.S. District Court ruling has invalidated specific Natera (NTRA) patents, providing a significant legal victory for NeoGenomics (NEO) and clearing the path for the commercialization of its RaDaR ST assay. This development was viewed by the market as a material positive, evidenced by a 24.55% surge in NEO's stock to $8.98. According to William Blair, this outcome was an "unexpected win" as the investment thesis was not heavily reliant on a near-term launch of its MRD strategy, with a potential broad commercial launch now projected for as early as Q4 2025. While NeoGenomics has already launched RaDaR ST for biopharma clients and is seeking CMS reimbursement, Natera is evaluating an appeal and emphasizes that the ruling does not affect its separate '035 patent, which previously resulted in an injunction against an earlier version of NeoGenomics' product. Despite the favorable ruling and stock reaction, William Blair maintains a Market Perform rating on NEO, indicating that investors will require greater confidence in the company's underlying execution before supporting a meaningfully higher valuation multiple.

Key Decisions for Investors

• Investors in NeoGenomics should view the court ruling as a significant de-risking event for the RaDaR ST assay, but recognize that material revenue contribution is contingent on a successful commercial launch in late 2025 and, crucially, securing CMS reimbursement.
• The ongoing legal risk should not be entirely dismissed; Natera's potential for an appeal and its assertion regarding the unaffected '035 patent could create future headline risk and legal uncertainty for NeoGenomics.
• Despite the 24.55% stock appreciation, the maintained 'Market Perform' rating from William Blair suggests a prudent approach may be to await evidence of sustained operational execution from NeoGenomics' management before significantly increasing a position, as the current rally may have priced in the immediate legal win.